- Case Report
- Open Access
Undifferentiated carcinoma of the liver: a case report with immunohistochemical analysis
© The Author(s). 2017
- Received: 13 November 2016
- Accepted: 5 January 2017
- Published: 10 January 2017
Undifferentiated carcinoma (UC) of the liver is extremely rare, and its clinicopathological characteristics have not been fully elucidated.
The present study reports the case of a 56-year-old male with UC of the liver. At 16 days post-admission, the patient suddenly succumbed due to intra-abdominal bleeding resulting from a ruptured liver. Macroscopic examination revealed that the hepatic parenchyma was almost completely replaced by innumerable minute nodules. Microscopically, the tumor demonstrated a diffuse proliferation of anaplastic cells that were positive for epithelial membrane antigen and neuron-specific enolase, suggesting neuroendocrine differentiation. Grimelius and Fontana-Masson staining were negative. Neuroendocrine markers were also negative, including chromogranin A, synaptophysin, and S-100 protein. Cytokeratin markers and mesenchymal markers were all negative. Tumor markers, such as α-fetoprotein and carcinoembryonic antigen, were also negative.
Although larger studies involving more patients are required to establish a therapeutic strategy, appropriate chemotherapy following an early diagnosis may be important to UC of the liver because the tumor behaves in an aggressive way.
- Undifferentiated carcinoma
- Neuroendocrine carcinoma
- Liver cancer
Undifferentiated carcinoma (UC) of the liver is an extremely rare malignant neoplasm [1, 2]. The clinicopathological characteristics and clinical course of UC have not been fully clarified, and a therapeutic strategy for unresectable cases has not been established. The present study reports the case of a 56-year-old male with UC of the liver, together with the results of immunohistochemical analysis.
Summary of reported cases of undifferentiated hepatocellular carcinoma of the liver
Extrapulmonary small cell carcinomas are extremely rare and can originate in a variety of sites, including the liver, colon, stomach, esophagus, cervix, gallbladder, and skin [9–14]. Zanconati et al.  reported three cases of unusual small cell primary carcinoma of the liver. All three tumors developed in non-cirrhotic livers and demonstrated rapid clinical evolution, with mortality ensuing between 1 and 5 months post-diagnosis. These tumors were comprised of broad nests of small epithelial cells positive for low-molecular weight keratins and AFP.
In the present case, the tumors were growing in a solid nest comprising small cells with hyperchromatic nuclei and scant cytoplasm, which indicated small cell carcinoma. By contrast, immunohistochemical analysis revealed positive staining for NSE, although it was negative for chromogranin A and synaptophysin, therefore suggesting neuroendocrine differentiation. It is difficult to determine which classification is appropriate for this type of tumor. The tumor is referred to as UC with neuroendocrine features, neuroendocrine carcinoma, or small cell carcinoma of the liver. Thus, a novel entity of the tumor should be established for the accumulation of such cases in the future.
UC grows invasively, features a high incidence of metastasis, and follows a rapid clinical course . However, no therapeutic strategies for unresectable tumors have been established. Moertel et al.  reported the chemotherapeutic results for metastatic UC with endocrine features and concluded that this type of tumor responded strongly to etoposide and cisplatin regimen chemotherapy. Similarly, Nakasuka et al.  reported a case of UC of the liver with neuroendocrine features treated with the same regimen that resulted in a positive clinical course. Other studies reported poorly differentiated/rapidly progressing neuroendocrine tumors  and poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas , which were treated with a combination of cisplatin and etoposide.
We herein reported the case of a 56-year-old male with UC of the liver. This tumor demonstrated a diffuse proliferation of anaplastic cells, which were positive for NSE suggesting neuroendocrine differentiation, and showed an aggressive behavior. Therefore, appropriate chemotherapy following an early diagnosis may be important to UC of the liver. In the future, larger studies on UC of the liver should be conducted to analyze an appropriate chemotherapeutic strategy for this rare disease.
The authors would like to thank Enago for the English language review.
All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Written informed consent was obtained from the patient for the publication of this case report and all accompanying images.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- Nakasuka H, Okada S, Okusaka T, Ishii H, Ikeda M, Ito R, Kosakamoto H, Yoshimari M, Nakanishi Y, Sakamoto M. Undifferentiated carcinoma of the liver with neuroendocrine features: a case report. Jpn J Clin Oncol. 1998;28:401–4.View ArticlePubMedGoogle Scholar
- Shimizu Y, Kaneko F, Motoori T, Yokomori H. Undifferentiated hepatocellular carcinoma difficult to distinguish from liver abscess. Intern Med. 2011;50:519–20.View ArticlePubMedGoogle Scholar
- Zhao M, Laissure JA, Zimmermann A. “Neuroendocrine” differentiation in hepatocellular carcinomas: immunohistochemical reactivity is related to distinct tumor cell types, but not to tumor grade. Histol Histopathol. 1993;8:617–26.PubMedGoogle Scholar
- Wang JH, Dhillon AP, Sankey EA, Wightman AK, Lewin JF, Scheuer PJ. ‘Neuroendocrine’ differentiation in primary neoplasms of the liver. J Pathol. 1991;163:61–7.View ArticlePubMedGoogle Scholar
- Tajima Y, Nakajima T, Sugano I, Nagao K, Kondo Y, Saito J. Hepatocellular carcinoma containing endocrine cells. An autopsy report of triplecancer involving the liver, kidney and thyroid. Acta Pathol Jpn. 1992;42:904–10.PubMedGoogle Scholar
- Ishida M, Seki K, Tatsuzawa A, Katayama K, Hirose K, Azuma T, Imamura Y, Abraham A, Yamaguchi A. Primary hepatic neuroendocrine carcinoma coexisting with hepatocellular carcinoma in hepatitis C liver cirrhosis: report of a case. Surg Today. 2003;33:214–8.View ArticlePubMedGoogle Scholar
- Pilichowska M, Kimura N, Ouchi A, Lin H, Mizuno Y, Nagura H. Primary hepatic carcinoid and neuroendocrine carcinoma: clinicopathological and immunohistochemical study of five cases. Pathol Int. 1999;49:318–24.View ArticlePubMedGoogle Scholar
- Bosman FT, Cameiro F, Hruban RH, et al. WHO classification of tumours of the digestive system. 2010.Google Scholar
- Zanconati F, Falconieri G, Lamovec J, Zidar A. Small cell carcinoma of the liver: a hitherto unnreported variant of hepatocellular carcinoma. Histopathology. 1996;29:449–53.View ArticlePubMedGoogle Scholar
- Jo JM, Cho YK, Hyun CL, Han KH, Rhee JY, Kwon JM, Kim WK, Han SH. Small cell carcinoma of the liver and biliary tract without jaundice. World J Gastroenterol. 2013;19:8146–50.View ArticlePubMedPubMed CentralGoogle Scholar
- Otten M, Sepehrkhouy S, van Everdingen K, Haas L. Primary small cell carcinoma of the liver, a rare entity. BMJ Case Rep. 2013;5:2013.Google Scholar
- Frazier SR, Kaplan PA, Loy TS. The pathology of extrapulmonary small cell carcinoma. Semin Oncol. 2007;34:30–8.View ArticlePubMedGoogle Scholar
- Kaman L, Iqbal J, Pall M, et al. Primary small cell carcinoma of liver: a rare tumor. Gastroenterology Res. 2010;3:180–4.PubMedPubMed CentralGoogle Scholar
- Kim YH, Kwon R, Jung GJ, et al. Extrapulmonary small-cell carcinoma of the liver. J Hepatobiliary Pancreat Surg. 2004;11:333–7.View ArticlePubMedGoogle Scholar
- Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991;68:227–32.View ArticlePubMedGoogle Scholar
- Fjällskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, Eriksson BK. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer. 2001;92:1101–7.View ArticlePubMedGoogle Scholar
- Iwasa S, Morizane C, Okusaka T, Ueno H, Ikeda M, Kondo S, Tanaka T, Nakachi K, Mitsunaga S, Kojima Y, Hagihara A, Hiraoka N. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol. 2010;40:313–8.View ArticlePubMedGoogle Scholar